Complement C1 inhibitor protein - CSL Behring

Drug Profile

Complement C1 inhibitor protein - CSL Behring

Alternative Names: Berinert; Berinert HS; Berinert P; C1 esterase inhibitor - CSL Behring; C1 esterase inhibitor concentrate; C1 inaktivator HS; C1-INH - CSL Behring; CE 1145; Complement C1 inactivator - CSL Behring; CSL 830; Human C1 esterase inhibitor concentrate

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator CSL Behring
  • Class Complement C1 inactivator proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angioedema
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase I/II Transplant rejection
  • Discontinued Reperfusion injury; Septic shock; Vascular disorders

Most Recent Events

  • 11 Nov 2016 CSL Behring plans a clinical trial for Reperfusion injury in Switzerland
  • 10 Nov 2016 Efficacy and adverse events data from the phase III COMPACT trial in Hereditary angioedema (In adolescents, In adults, Prevention) (SC) presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (AAAAI-2016)
  • 30 Aug 2016 The US FDA accepts BLA for complement C1 inhibitor protein (SC) for Hereditary angiodema (Prevention) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top